As described in detail below, general observations from these experiments include potentiation of the anti-proliferative effects of midostaurin by inhibitors targeting SYK, which supports the notion that additional SYK suppression is of benefit against FLT3-ITD-driven AML treated with a FLT3 kinase inhibitor. Here, FLT3 is linked to acute myeloid leukemia.